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Abstract TRIM16 exhibits tumour suppressor functions
by interacting with cytoplasmic vimentin and nuclear E2F1
proteins in neuroblastoma and squamous cell carcinoma
cells, reducing cell migration and replication. Reduced
TRIM16 expression in a range of human primary malig-
nant tissues correlates with increased malignant potential.
TRIM16 also induces apoptosis in breast and lung cancer
cells, by unknown mechanisms. Here we show that
overexpression of TRIM16 induces apoptosis in human
breast cancer (MCF7) and neuroblastoma (BE(2)-C) cells,
but not in non-malignant HEK293 cells. TRIM16 increased
procaspase-2 protein levels in MCF7 and induced caspase-
2 activity in both MCF7 and BE(2)-C cells. We show that
TRIM16 and caspase-2 proteins directly interact in both
MCF7 and BE(2)-C cells and co-localise in MCF7 cells.
Most importantly, the induction of caspase-2 activity is
required for TRIM16 to initiate apoptosis. Our data suggest
a novel mechanism by which TRIM16 can promote
apoptosis by directly modulating caspase-2 activity.
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Introduction
The tripartite motif or TRIM, family of proteins were
originally described by its multi-domain design of three
structurally distinct motifs, the RING finger zinc-binding
domain, a B-box zinc-binding domain and the coiled-coil
domain [1]. Presently, there are approximately 70 TRIM
proteins which are structurally similar, yet involved in a
diverse range of cellular processes including cell prolifer-
ation and differentiation, oncogenesis, apoptosis and ret-
roviral replication [2, 3]. TRIM protein functions
commonly relate to direct regulatory protein–protein
interactions [4]. Since its identification in human mammary
epithelial cells, several studies have documented the
important physiological functions of the Tripartite Motif 16
(TRIM16) protein in cellular biology. While TRIM16 lacks
the RING finger protein domain, it is comprised of two
B-box domains that are followed by a coiled-coil region
and a C-terminal, RFP/B30.2-like domain [5, 6]. A sig-
nificant number of TRIM proteins positively or negatively
regulate pathways associated with tumour progression and
suppression, thus acting as oncogenes or tumour suppres-
sors, respectively [4]. Some TRIMs, such as TRIM13,
TRIM8, and TRIM32, function as tumour suppressor pro-
teins through regulation of transcription and apoptosis [7–
9]. While other TRIM proteins, such as TRIM27/RFP and
TRIM24/TIF1a, function normally as tumour suppressor
proteins, but acquire oncogenic activity when fused to
kinases by tumour-associated chromosomal rearrange-
ments [1].
TRIM proteins inhibit tumour development through
multiple mechanisms, and one common pathway relates to
the activation of apoptosis. A large network of interacting
proteins mediates the highly orchestrated pathways of
programmed cell death [10], and several TRIM proteins
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have been characterised as having regulatory roles in ini-
tiating and executing apoptosis. Overexpression of
TRIM13 stabilises p53 and induces apoptosis [7], while
TRIM27/RFP triggers apoptosis via stress-response kinases
and caspases [1]. In addition to inducing apoptosis by
activating tumour necrosis factor [8], TRIM32 enhances
neural differentiation by acting as a co-activator of retinoid
receptor, RARa-mediated transcription which promotes
neural differentiation [9]. Similar to these proteins,
TRIM16 acts as a tumour suppressor protein through
inhibitory effects on cell growth, migration, proliferation,
as well as induction of apoptosis [11–14].
TRIM16 is also known as the estrogen-responsive B-box
protein due to its original discovery as an estrogen-
responsive protein in human mammary epithelial cells [6].
Further characterisation has implicated TRIM16 in an array
of functions in human physiology. Estrogens and kerati-
nocyte growth factor regulate mRNA expression levels of
TRIM16 in human mammary epithelial cells and kerati-
nocytes, respectively [5, 6]. Increased expression of
TRIM16 induced the differentiation of keratinocytes [5]. In
addition to these roles, TRIM16 interacts via its C-terminal
RFP/B30.2-like domain with the components of the in-
flammasome and increases the secretion of IL-1b,
enhancing innate immunity [15].
Like TRIM24/TIF1a and TRIM32, TRIM16 has been
shown to suppress tumour progression through regulatory
pathways involved in growth inhibition, migration, differ-
entiation and apoptosis [12–14]. TRIM16 was identified as
a key regulator of the retinoid anti-cancer signal in human
neuroblastoma and breast cancer cell lines [12, 14].
TRIM16 enhanced and restored the growth inhibitory and
anti-proliferative effects of retinoids through up-regulation
of retinoid target genes, RARb and CYP26A1 [11, 14].
TRIM16 protein expression in primary tissues from human
neuroblastoma and squamous cell carcinoma of skin is
decreased in the more malignant phenotype [12, 13].
Decreased cellular proliferation and migration of neuro-
blastoma and squamous cell carcinoma cell lines by
directly interacting with and reducing protein stability of
cytoplasmic Vimentin and nuclear E2F1, respectively [12,
13]. Most recently, we have demonstrated that TRIM16
can heterodimerize with other TRIM proteins and has E3
ubiquitin ligase activity [16].
Enforced overexpression of TRIM16 induces apop-
tosis in MB-MDA-231 breast and SK-MES-1 lung
cancer cells [14], however, the exact mechanisms of
TRIM16 involvement in the regulation of apoptosis
remains unclear. In this study, we show that overex-
pression of TRIM16 induced apoptosis in malignant, but




BE(2)-C cell line was gifted by Dr. J. Biedler (Memorial
Sloan–Kettering Cancer Center, New York). MCF7 and the
human embryonic kidney 293 cells (HEK 293) were pur-
chased from the American Type Culture Collection. All
cells were cultured at 37 C in 5 % CO2 as adherent
monolayer in Dulbecco modified Eagle medium (Life
Technologies) supplemented with L-glutamine and 10 %
foetal calf serum.
Transient transfection of plasmid DNA or siRNA
Full-length human TRIM16 plasmid DNA as described
previously [11], was used for overexpression and transient
transfections. siRNAs specific to TRIM16 (Dharmacon)
and caspase-2 (Dharmacon) were used for knock-down.
pcDNA3.1-Myc/His EV plasmid (Life technologies) and
On-Target Plus scramble RNA (Dharmacon) were used as
transient transfection controls. Sequences for TRIM16
siRNA were ACCUGCAUGGUGAAUUACUUU and
caspase-2 siRNA were GCCUUGCACUCCUGAAUUU.
Trypan blue exclusion cell viability assay
Human MCF7 breast cancer cells (1 9 106 cells/flask)
were transfected with either TRIM16-Myc/His or EV
control and incubated for 24 and 48 h. At each time point
the cells were harvested and mixed with trypan blue.
Viable cells were counted on a haemocytometer.
TUNEL apoptosis assay
TRIM16 overexpressing or EV transiently transfected
(control) MCF7, BE(2)-C and HEK293 cells were stained
with TUNEL TMR dye using the In Situ Cell Death
Detection Kit (Roche) according to the manufacturer’s
protocol. Samples were analysed using IF microscopy with
a Zeiss Axiovert 200 M fluorescent microscope coupled to
an AxioCamMR3 camera and driven by the Axio vision
software. TUNEL positive cells were counted in each
sample for quantification.
Western immunoblot analysis and antibodies
Whole cell lysates were obtained with NP-40 cell lysis
buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 % (v/v)
IGEPAL). To isolate and separate cytosolic and mito-
chondrial proteins, the mitochondrial isolation kit (Thermo
Scientific) was used according to the manufacturer’s
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protocol. Protein concentrations were measured with the
BCA protein assay (Thermo Scientific). A final total of
20 lg whole cell protein extracts were loaded onto 4–20 %
Criterion Tris–HCl gels (Bio-Rad) and then transferred
onto nitrocellulose membranes for antibody detection.
Antibodies used for Western immunoblots were mouse
monoclonal antibodies for Myc-tag; 1:4,000, (Cell Sig-
nalling Technologies) and GAPDH; 1:10,000, (Abcam).
Rabbit polyclonal antibodies were for caspase-2; 1:500,
(Abcam), cytochrome c; 1:1,000, (Cell Signalling Tech-
nologies), TRIM16; 1:4,000 (Bethyl Laboratories) and
topoisomerase 1; 1:10,000 (Novus Biologicals).
Immunoprecipitation assay
Protein lysates (200 lg) from TRIM16-Myc/His and EV
(control) transiently transfected MCF7 cells were used for
co-immunoprecipitation (co-IP) studies. Recombinant
TRIM16-Myc/His was pulled-down from the sample using
BcMag His Magentic beads (Bioclone Inc) according to
the manufacturer’s protocol. Samples were analysed for
interaction with Western immunoblots as described earlier.
IF confocal microscopy
MCF7 cells (1 9 104 cells/well) were grown in eight-well
chamber slides and transiently transfected with TRIM16-
Myc/His or EV (control) and incubated for 48 h. Cells were
then fixed in 4 % (v/v) paraformaldehyde and the non-specific
staining was blocked with 10 % (w/v) BSA. TRIM16-Myc/
His was detected with mouse monoclonal Myc-tag antibody
and caspase-2 was detected with rabbit polyclonal caspase-2
antibody. Samples were then incubated with Alexa Fluor 499
goat anti-mouse and Alexa Fluor 555 goat anti-rabbit. After
the staining, the cells were mounted in ProLong Gold Antifade
reagent with DAPI (Life Technologies). Images were
obtained with the Olympus Fluoview FV1000.
Caspase-2 activity assays
Activity of caspase-2 was measured in the whole protein
lysates of TRIM16 and EV (control) transiently transfected
MCF7 cells using the caspase-2 colourimetric assay kit (Ab-
cam), following the manufacturer’s protocol. Active forms of
caspase-2 were detected by Western immunoblots as descri-
bed above. To inhibit the activity of caspase-2, cell samples
were treated with, 20 lM Z-VDVAD-FMK, (BioVision).
JC-1 mitochondrial membrane potential assay
The mitochondrial membrane potential of TRIM16-Myc/
His and EV transiently transfected MCF7 cells was mea-
sured following the protocol of the MitoProbeTM JC-1
assay kit. Non-treated MCF7 cells served as controls for
the assay. Mitochondrial depolarisation was measured by
flow cytometry using the FACSCalibur.
Statistical analysis
Statistical significance was evaluated using one-way
ANOVA followed by Bonferroni’s multiple comparison
post-test. P values \0.05 were considered statistical sig-
nificant. GraphPad Prism 5 (La Jolla, CA) was used for
statistical analysis.
Results
TRIM16 induces apoptosis in MCF7 breast cancer, and
BE(2)-C neuroblastoma cells but not in the non-malignant
HEK293 cells.
We have previously shown increased apoptosis of MD-
MBA-231 breast and SK-MES-1 lung cancer cells fol-
lowing forced expression of TRIM16 [14]. Here we first
showed that apoptosis was a general feature of other cancer
cell types, in this case MCF7 breast and BE(2)-C neuro-
blastoma cancer cell lines, following enforced overex-
pression of TRIM16 (Fig. 1a). Apoptotic cells were
detected by TUNEL stain in MCF7 and BE(2)-C cells at
48 h after transient transfection of a TRIM16 expression
vector, in contrast to the absence of any apoptotic cells in
empty vector (EV) control cells (Fig. 1a). Quantitative
analysis of the TUNEL images indicated an almost 80 %
(P \ 0.001) increase in apoptotic cells in the TRIM16
overexpressing MCF7 and BE(2)-C cells compared to the
EV control samples (Fig. 2b). In comparison, non-malig-
nant HEK293 cells transfected with TRIM16 demonstrated
negligible induction of apoptosis (Fig. 1a, b). Efficiency of
the MYC-tagged TRIM16 plasmid DNA was measured by
staining the transiently transfected MCF7, BE(2)-C and
HEK293 cells with Alexa FluorR 488 fluorescent antibody
(Fig. 3c). Quantitation of the TRIM16 transfected cells
indicated that approximately 60 % of the MCF7, BE(2)-C
and HEK293 cells were transfected.
TRIM16 regulates procaspase-2 protein levels
Caspases are the major proteins which initiates, regulates and
executes apoptosis. We have previously performed cDNA
microarray analysis and found that TRIM16 overexpression
resulted in an increase in caspase-2 expression in neuro-
blastoma cancer cells. To investigate this further, TRIM16
was modulated in MCF7, BE(2)-C and HEK293 cells using
transfection and siRNA technology. TRIM16 overexpres-
sion in MCF7, BE(2)-C and HEK293 cells resulted in an
increased procaspase-2 protein levels in MCF7 cells at both
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24 and 48 h time-points post-transfection, compared to EV
controls. However, the increase in procaspase-2 was only
observed in the MCF7 cells, but not in BE(2)-C and HEK293
cells (Fig. 2a–c). Conversely, inhibition of TRIM16 protein
expression by a specific siRNA lowered expression levels of
procaspase-2. A significant decrease in procaspase-2
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expression was observed in the MCF7 cells at 24 and 48 h
post-TRIM16 knock-down compared to the control siRNA
(Fig. 2d). Similar decrease in procaspase-2 expression was
also observed in BE(2)-C cells after siRNA inhibition of
TRIM16 expression (Fig. 2e), albeit to a lesser extent. As
expected knock-down of TRIM16 expression had no effect
on the protein levels of procaspase-2 in the HEK293 cells
(Fig. 2f). Together, these results suggest that TRIM16 can
induce apoptotic cell death through modulating procaspase-
2 levels.
Chemical inhibition of caspase-2 suppresses
TRIM16-induced caspase-2 activity and cell death
To better elucidate the effects of TRIM16 on caspase-2, we
investigated caspase-2 activation using immunoblot anal-
ysis. Protein lysates from MCF7 and BE(2)-C cells over-
expressing TRIM16 were immunoblotted with an antibody
which recognises the activated or cleaved form of caspase-
2. In Fig. 3a forced overexpression of TRIM16 caused a
two fold increase (P B 0.001) p value in the active form of
caspase-2 at 48 h post-transfection. These regulatory
effects of TRIM16 on caspase-2 protein levels were
greatest in MCF7 cells, compared with BE(2)-C cells
(Fig. 3a). Thus, further characterisation of the molecular
functions of TRIM16 on caspase-2 was conducted mostly
in the MCF7 cancer cells. To examine the role of TRIM16
in regulating caspase-2 activity, we measured caspase-2
activity by colorimetric assay. Activity assays on the
MCF7 whole cell lysates of cells transiently transfected
Fig. 2 TRIM16 regulates
procaspase-2 protein levels. a–c
MCF7, BE(2)-C and HEK293
cells were transiently
transfected with TRIM16
plasmid for 24 and 48 h.
Western immunoblots of total
protein extracts were analysed
using antibodies specific to
Myc-tag and caspase-2. Empty
vector (EV) transfection was
used as negative control.
Topoisomerase-1 protein was
used as the loading control. d–f
TRIM16 protein expression was
knock-downed in MCF7,
BE(2)-C and HEK293 cells
using specific siRNA to
TRIM16. Total protein extracts
were analysed with
immunoblots using antibodies
specific to TRIM16 and
caspase-2. Control siRNA
(siRNA) transfected cells were
used as negative controls.
Topoisomerase-1 was used as
the loading control
Fig. 1 TRIM16 induces apoptosis in breast and neuroblastoma
cancer cells. a Apoptosis was detected in MCF7 and BE(2)-C cancer
cells overexpressing TRIM16 at 48 h post-transfection using the
TUNEL TMR dye. No apoptosis was detected in the non-cancer
HEK293 cells. b TUNEL TMR dye stained positive apoptotic cells
were quantitated using fluorescence microscopy, 48 h post-transfec-
tion (***P \ 0.001). c Expression of the transiently transfected
MYC-tagged TRIM16 in the MCF7, BE(2)-C and HECK293 cells
were detected by IF staining of the transfected TRIM16 protein
(green) (Color figure online)
b
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with TRIM16, showed more than a two-fold (P \ 0.001)
increase at 48 h, while no significant changes were detec-
ted in EV control cells (Fig. 3b). These data show a cor-
relation between increased caspase-2 activities and
increased levels of active caspase-2 protein. When the
caspase-2 inhibitor, VDVAD (20 lM), was added to the
whole cell lysates, caspase-2 activity was not detected
(Fig. 3b). To determine whether TRIM16-induced activa-
tion of caspase-2 activity is required for the initiation of
apoptosis, the TRIM16 overexpressing MCF7 cells were
Fig. 4 TRIM16 directly
interacts, and co-localises, with
caspase-2. a Total protein
extracts from MCF7 and BE(2)-
C cells transiently transfected
with TRIM16 (TRIM16 input
lane) or EV control (EV input
lane) were incubated with His-
specific magnetic beads.
Purified immunoprecipitated
complexes were analysed by
Western blot with antibodies
specific to MYC (TRIM16) and
caspase-2. b Immunofluorescent
confocal microscopy images of
TRIM16-Myc/His transiently
transfected MCF7 cells after
transfection 48 h. TRIM16
protein was detected with MYC
antibody and secondary Alexa
Flour 488 antibody (green).
Caspase-2 was detected with
caspase-2 specific antibody and
secondary Alexa Flour 555
(red) antibody, nuclear was
staining using DAPI (blue)
(Color figure online)
Fig. 3 Chemical inhibition of caspase-2 suppresses TRIM16-induced
caspase-2 activity and cell death. a Western immunoblot analysis of anti-
procaspase-2 and caspase-2 active isoforms 24 and 48 h post transient
transfection of TRIM16 in MCF7 and BE(2)-C cells. GAPDH was used
as the loading control. b Caspase-2 activity levels at 24 and 48 h post
TRIM16 transient transfection of MCF7 cells (***P \ 0.001). c Apop-
tosis analysis by the TUNEL TMR dye of TRIM16 overexpressing
MCF7 cells treated with the caspase-2 inhibitor VDVAD (40 lM). EV
and TRIM16 transient transfected cells were used as negative and
positive controls, respectively. d MYC-tagged transiently transfected
MCF7 cells were detected by staining with MYC-tag antibody and
fluorescent secondary antibody (green) (Color figure online)
b
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treated with the caspase-2 inhibitor VDVAD (40 lM)
(Fig. 3c). These cells remained viable as determined by the
lack of TUNEL staining of the cells and comparison with
the staining observed in non-treated control cells (Fig. 3c).
To confirm the transient transfect of MYC-tagged TRIM16
in the MCF7 cells, the cells were stained with MYC-tag
antibody and fluorescent secondary antibody. Immunoflu-
orescent images show that the MCF7 cells were transfected
with MYC-tagged TRIM16 (Fig. 3d). The results further
suggest that TRIM16 has a role in the activation process of
caspase-2 and that activity of this caspase appears crucial
for TRIM16-mediated apoptosis.
TRIM16 directly interacts, and co-localises,
with caspase-2
Our data suggested that TRIM16 induces apoptotic cell
death through modulating procaspase-2. Since TRIM pro-
teins are known to regulate cellular mechanisms through
protein–protein interactions [4], thus, we examined whe-
ther there was a direct interaction of these proteins by co-IP
and IF microscopy. Direct interaction of TRIM16 and
caspase-2 in MCF7 and BE(2)-C cells was analysed by
using His-tag specific magnetic beads. Protein lysates from
cells transiently transfected with a TRIM16-Myc/His tag-
ged expression vector were incubated with the His-tag-
specific magnetic beads. Protein complexes that formed
with TRIM16 were then analysed by Western immunoblot
analysis. Detection of TRIM16-Myc/His with the Myc-tag-
specific antibody found that TRIM16 protein was specifi-
cally pulled-down with the magnetic beads in both MCF7
and BE(2)-C cells, indicating that caspase-2 bound directly
to TRIM16 and was precipitated in the complex with the
magnetic beads (Fig. 4a). In order to determine the local-
isation of the TRIM16 and caspase-2 interaction, tran-
siently transfected MCF7 cells were analysed by indirect IF
confocal microscopy using antibodies to myc-TRIM16
(green) and caspase-2 (red). The results showed that
TRIM16 is predominantly located in the cytoplasm, while
caspase-2 is expressed in both the cytoplasm and the
nucleus. However, the two proteins were found to co-
localise in the cytoplasm of MCF7 cells (Fig. 4b).
TRIM16 overexpression induces depolarisation
of the mitochondrial membrane potential
and cytochrome c release
Caspase-2 has been previously reported to activate an
intrinsic apoptotic pathway, dependent on the mitochondria
[17, 18]. Thus, mitochondrial membrane potential was
examined by flow cytometry after the overexpression of
TRIM16 in MCF7 using MitoProbeTM JC-1. A significant
increase in the rate of mitochondrial depolarisation of 40 %
(P \ 0.001) was observed following the activation of
caspase-2 by the overexpression of TRIM16 (Fig. 5a, b).
Depolarisation of mitochondrial membrane potential
occurred at 48 h post-TRIM16 overexpression, while
minimal depolarisation was detected at 24 h (data not
shown). Inhibition of caspase-2 activity by the caspase-2
inhibitor VDVAD (40 lM) prevented this depolarisation
(Fig. 5a, b).
Cytochrome c release into the cytoplasm is a common
event following mitochondrial depolarisation, and several
reports indicate activation of caspase-2 lies upstream of
mitochondrial depolarisation [17, 18]. Therefore, the iso-
lated cytoplasmic extracts from TRIM16 overexpressing
MCF7 cells were analysed by immunoblot using antibodies
to the Myc-tagged TRIM16 or cytochrome c. As antici-
pated, increasing amounts of cytochrome c were detected
in the cytoplasmic extracts of TRIM16 overexpressing
MCF7 cells over 48 h (Fig. 5c). Moreover, inhibition of
caspase-2 activity by the caspase-2 inhibitor VDVAD in
cells transient transfected with TRIM16 prevented the
mitochondrial release of cytochrome c into the cytoplasm
(Fig. 5c). Fractionation of the cytoplasmic and mitochon-
drial proteins were confirmed by using the tubulin and
VDAC1/Porin antibodies as cytoplasmic and mitochondrial
protein markers, respectively (Fig. 5d).
Although caspase-2 is the most specific caspase that is
uniquely inhibited by VDVAD, the validity of the data
obtained with this inhibitor were further confirmed by the
use of caspase-2 specific siRNA to knock-down caspase-2
protein expression. Comparison of the procaspase-2 levels
between the cells overexpressing TRIM16 alone and cells
transfected with both TRIM16 expression vector and pro-
caspase-2 siRNA shows significant decreases in pro- and
active caspase-2 protein levels (Fig. 6a). Inhibition of
caspase-2 expression also prevented the mitochondrial
release of cytochrome c, in the TRIM16 overexpressing
MCF7 cells (Fig. 6a). Furthermore, mitochondrial depo-
larisation was also prevented by the siRNA inhibition of
Fig. 5 TRIM16 overexpression induces depolarisation of mitochon-
drial membrane potential and cytochrome c release. a, b Flow
cytometry analysis for mitochondrial membrane depolarisation was
performed in MCF7 cells transiently transfected with EV or TRIM16
(***P \ 0.001). TRIM16 overexpressing samples treated with
caspase-2 inhibitor VDVAD were also analysed by flow cytometry
(*** P \ 0.001). Non-treated MCF7 cells were used as the negative
control. c The cytoplasmic extracts of TRIM16 transiently transfected
MCF7 cells, treated with either DMSO or VDVAD were isolated and
analysed by immunoblot using cytochrome c antibody. Tubulin was
used a cytoplasmic protein loading control and GAPDH was used as
the total protein loading control. Myc-tag antibody was used as for
confirmation of TRIM16 plasmid transfection. d Fractionation of the
cytoplasmic and mitochondrial proteins from the TRIM16 transiently
transfected MCF7 cells were confirmed by using the cytoplasmic
protein marker tubulin and the mitochondrial protein marker VDAC1/
Porin
b
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caspase-2 expression (Fig. 6b, c). These data reveal that
inhibiting caspase-2 protein expression by siRNA knock-
down has same effects on apoptosis as the caspase-2
inhibitor VDVAD. Thus, TRIM16 requires caspase-2
activity for mitochondrial depolarisation and the induction
of apoptosis.
Discussion
Regulatory proteins which have been associated with pro-
grammed cell death are under intense investigation as
potential cancer therapeutic targets. Determining the cel-
lular processes which lead to activation of caspases during
apoptosis, and the relevant intracellular caspase substrates
and regulators, are a vital link in the pathway toward
potential therapies [17]. Execution of apoptosis requires the
accurate co-ordination of the cell death-specific proteases,
the caspase protein family. Using a biochemical approach,
our data presented in this study describes a novel mecha-
nism of TRIM16-induced apoptosis that requires the acti-
vation and enzymatic activity of caspase-2.
Recently, the multifunctional cellular protein, TRIM16,
has been shown to inhibit the growth and proliferation of
several different human cancer cell lines [11–14]. These
studies describe many regulatory roles of TRIM16, one of
which involves E2F1 protein degradation that causes
growth inhibition of cancer cells [12, 13]. Here we have
shown that TRIM16 upregulates caspase-2 protein levels in
breast cancer and neuroblastoma cells but not non-malig-
nant cells. It is possible that as a result of increased levels
of TRIM16, procaspase-2 increases and reaches a threshold
for its activation, which initiates apoptosis.
Caspase-2 is an enigmatic caspase with active roles in
both cell cycle regulation and programmed cell death [19,
20]. The enzyme also has the physiochemical properties of
both an initiator and effector caspase [21]. Caspase-2
knock-out mice develop normally and are viable, while the
absence of caspase-2 expression in the presence of an
oncogenic signal led to the formation of aggressive
tumours in immunodeficient mice [22], suggesting that this
particular caspase is a tumour suppressor protein [22]. It
has been shown that dimerization and cleavage are essen-
tial for functional activation of caspase-2 in apoptosis [23–
25], and there are two known mechanisms of caspase-2
activation, and each mechanism involves different regula-
tory proteins. An activation platform known as the PID-
Dosome, is a trimolecular complex consisting of PIDD (a
p53-induced protein with a death domain), RAIDD
(receptor-interacting protein-associated ICH1/CED3
homologous protein with a death domain) and procaspase-2
[25]. Procaspase-2 proteins recruited to this activation
platform and then dimerise. Upon dimerization,
autocatalytic cleavage occurs and activated forms of cas-
pase-2 are generated [23, 24, 26].
Another caspase-2 activation platform is instigated by
the formation of a large multi-protein complex known as
the death-inducing signalling complex (DISC). DISC for-
mation requires up-regulation of CD95 by p53 and the
recruitment of FADD and procaspase-8 [27–29]. Upon
formation of the DISC complex, caspase-8 cleaves pro-
caspase-2 resulting in activation of this caspase [28].
Unlike the PIDDosome, the interaction of procaspase-2
with the DISC complex occurs transiently [28]. As
enforced overexpression of TRIM16 increases caspase-2
activity by more than 2-fold, it is highly plausible that
TRIM16 may have a novel role in either of these activation
platforms. It is possible that TRIM16 mediates the
recruitment of caspase-2 to a platform to initiate the
dimerisation and cleavage process. Similarly to the direct
mediatory roles of TRIM16 in the pRb/E2F1 in cell cycle
control pathway, TRIM16 may also be directly involved in
caspase-2 regulation and activation for the initiation of
apoptosis. The data obtained from MCF7 cancer cells
suggested that all the cell death effects of TRIM16 over-
expression required the integrity as well as the functional
activation of caspase-2.
Almost all of the TRIM proteins regulate cellular
function through protein–protein interactions. Inactive
initiator caspases with long pro-domains contain specific
protein–protein interaction motifs, which suggest these
proteolytic enzymes are regulated prior to cleavage and
subsequent activation [28, 30]. A physical interaction of
TRIM16 with procaspase-2 in the cytoplasm of MCF7 cells
suggests that TRIM16 may have a central role upstream of
caspase-2 activation. Further studies are needed to provide
evidence, and may prove that TRIM16 has a direct func-
tional role in the recruitment and activation of caspase-2.
This direct protein–protein interaction between TRIM16
and caspase-2 also suggests that TRIM16 may be involved
in the PIDDosome caspase-2 activation platform, as the
molecules in this complex are known to directly interact in
the cytoplasm of cells [25].
Depolarisation of mitochondrial membrane potential
results in the release of proapoptotic mitochondrial pro-
teins, such as cytochrome c into the cytoplasm [31].
Fig. 6 Caspase-2 activation, release of cytochrome c and mitochon-
drial depolarisation are required for TRIM16 induced apoptosis.
a MCF7 cells were transiently transfected with EV control, TRIM16
plasmid, siRNA specific to caspase-2 or a combination of TRIM16
plasmid and caspase-2 siRNA for 48 h and analysed by immuno-
blotting with antibodies specific to MYC-TRIM16, caspase-2 and
cytochrome c. GAPDH protein was used as the loading control. b, c
Flow cytometry analysis for mitochondrial membrane depolarisation
of MCF7 cells transfected with EV/siRNA control, TRIM16 plasmid
and TRIM16 plasmid plus siRNA specific to caspase-2 was
performed by using the MitoProbeTM JC-1 assay kit (***P \ 0.001)
c
648 Apoptosis (2013) 18:639–651
123
Apoptosis (2013) 18:639–651 649
123
Caspase-2, through the cleavage of Bid activates Bax/Bak
which form pores in the outer mitochondrial membrane
allowing the release of proapoptotic proteins [29]. Upon
release into the cytoplasm, cytochrome c activates the
Apaf-caspase-9 apoptosome complex [17]. This mecha-
nism lies downstream of caspase-2 activation and is
required by caspase-2 to activate executioner caspases [17,
18]. Since TRIM16 has a central role involved in the
activation process it is possible that, TRIM16 is a novel
protein that has the potential to initiate the mitochondria-
dependent intrinsic apoptosis pathway.
Caspase-3, also known as the death enzyme, has a crucial
role in the controlled execution of programmed cell death.
Many mechanisms involved in the intrinsic and extrinsic
pathways of apoptosis require the activation of caspase-3
[32]. However, caspase-3 was not identified to be up-regu-
lated in the TRIM16 overexpression microarray analysis
(unpublished data). In addition, caspase-3 is an executioner
caspase that has downstream functions in apoptosis, while
caspase-2 is an initiator caspase with upstream functions in
apoptosis. Furthermore, due to a deletion, MCF7 breast
cancer cells lack of functional capacity to express caspase-3
[33]. Despite the absence of this central death caspase, our
data suggested that TRIM16 induces cell death of MCF7
cells through the activation of caspase-2. Activation of cas-
pase-2 alone is insufficient to execute all the downstream
processes necessary for apoptosis. It is possible that once
activated by TRIM16, caspase-2 is able to execute pro-
grammed cell death through alternate pathways activating
other executioner caspases, such as caspase-7 [34].
Caspase-2 is a crucial component of the TRIM16-
induced apoptosis pathway in MCF7 cells. Our results
suggest that TRIM16-mediated apoptosis and the mecha-
nisms leading to cell death are dependent on the functional
integrity of caspase-2. However, some studies have ques-
tioned that the specificity of the inhibitor VDVAD in
caspase-2 inhibition [35]. Although caspase-2 is specifi-
cally targeted by VDVAD, caspases—3, 7 and 10 were
shown to have only limited activity when exposed to this
same substrate [36]. Hence, to further confirm the role of
caspase-2 in TRIM16 induced apoptosis, caspase-2 protein
expression was knocked-down by specific siRNA. Near
identical effects are observed with the siRNA knock-down
of caspase-2 and the use of the inhibitor. With reduced
caspase-2 protein expression, no active isoforms of cas-
pase-2 were detected. The mitochondrial depolarisation did
not occur and no cytochrome c was released into the
cytoplasm. Thus, inhibiting caspase-2 by either protein
knock-down or pharmacological inhibition reveals that
TRIM16 requires the activation and activity of caspase-2 to
function as an apoptotic molecule.
Taken together, our data reveal a novel mechanism, by
which cells overexpressing TRIM16 can induce apoptosis in
cancer cells, but not in non-malignant cells. It may be due to
repressed and deregulated TRIM16 protein expression in
cancer cells, but not in normal cells. TRIM16 directly
interacts, and co-localises, with caspase-2, resulting in the
depolarisation of mitochondria and a corresponding cyto-
chrome c release. This mechanism and pathway is specific to
cancer cells, where TRIM16 expression is often reduced and
further supports the role of TRIM16 as a tumour suppressor
protein.
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